None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients with RA who fulfill the 1987 ACR classification criteria for RA and diagnosed at least 6 months before enrollment. 2) DAS28-ESR < 3.2 in two consecutive examinations apart for at least 1 month 3) Regularly taking any type of NSAID for more than 4 weeks (irrespective of dose) 4)Patient who take regularly takes less than 7.5mg of oral steroids over a month. 5)Patients who understand about the study, and provided informed consent
Exclusion criteria
Exclusion criteria: 1) Patients enrolled in other phase 1,2,3 clinical trials. 2) Patients who had any type of adverse effects of acetaminophen (Patients who has elevated AST/ALT levels more than 2 times of upper normal range of reference value) 3) Patients with concurrent fibromyalgia or severe osteoarthritis with Kellgren grade III/IV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients who do not take any type of NSAID(Non-Steroidal Anti-Inflammatory Drugs) during the 16 weeks of study period | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of DAS-28 score during study period ;Change of RAPID3(Routine Assesment of Patient Index Data) score during study period;Clinical characteristics of patients who re-start any type of NSAID(Non-Steroidal Anti-Inflammatory Drugs) during study period;Clinical characteristics of patients who do not take any type of NSAID(Non-Steroidal Anti-Inflammatory Drugs) during study period | — |
Countries
Korea, Republic of
Contacts
Seoul Metropolitan Government Seoul National University Boramae Medical Center